Qilian International Holding Group Limited engages in the research, development, and production of active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivative (TCMD) products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings comprising Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.
IPO Year: 2021
Exchange: NASDAQ
Website: qlsyy.net
| Date | Price Target | Rating | Analyst |
|---|
CHENGDU, China, Aug. 13, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that effective on August 11, 2024, its Class A ordinary shares will begin trading on the Nasdaq Capital Market under the ticker symbol "BGM". The new ticker symbol will replace the Company's current ticker symbol "QLI." No action by the Company's shareholders is required with respect to the ticker symbol change. The Company's Class A ordinary shares will continue to be listed on the Nasdaq Capital Market and the CUSIP number remains unchanged. About Qilian International Holding Group L
CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on July 10, 2024, NASDAQ notified the Company that it has determined that for the 10 consecutive business days, from June 21, 2024 to July 9, 2024, the closing bid price of the Company's Class A ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter. About Qilian International Holding Group Ltd Qilian International Holding Group Ltd, headquartered in Gansu, China, is
CHENGDU, China, June 18, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced today that an 1 for 5 reverse split of its authorized share capital, was approved by the Company's board of directors on May 29, 2023 and will become effective on June 21, 2024. In connection with the reverse share split, the Company's shareholders will receive one new Class A ordinary share or Class B ordinary share of the Company for every five Class A ordinary shares or every five Class B ordinary shares they hold, respectively. The Company's Class A ordinary shares are expected to begi
JIUQUAN, China, May 17, 2024 /PRNewswire/ -- Qilian International Holdings Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a pharmaceutical and chemical products manufacturer headquartered in China, today announced: In the past two years, Qilian International Holdings Group Limited has encountered significant challenges stemming from the continuous shrinkage in market demand for its oxytetracycline products, coupled with a persistent decline in market prices and escalating environmental protection standards. These factors have collectively led to a substantial increase in the production and operational costs for Qilian International, consequently impairing the profitability of the ox
JIUQUAN, China, Jan. 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on January 10, 2024, the Company received a written notification from the Nasdaq's Listing Qualifications Department, granting the Company another 180 calendar days extension, or until July 8, 2024, to regain compliance with Nasdaq's minimum bid price requirement. The Company can cure this deficiency if the closing bid price of its ordinary shares is $1.00 per share or higher for at least 10 consecutive business days during this second compliance period. The Company intends to
JIUQUAN, China, July 17, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, received notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq"), dated July 13, 2023, that the Company is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on The Nasdaq Global Market (the "Nasdaq Global Market"). The Notification Letter is only a notification of deficiency and not a notice of delisting. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per
JIUQUAN, China, April 26, 2023 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, previously announced that on February 16, 2023, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("NASDAQ") indicating that the Company was not in compliance with NASDAQ Listing Rule 5250(c)(1) for continued listing (the "Rule") as a result of not having timely filed its annual report on Form 20-F for the year ended September 30, 2022. On April 19, 2023, the Company filed the Form 20-F, and on April 20, 2023, the Company received a s
JIUQUAN, China, Feb. 23, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced it has received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on February 16, 2023 stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended September 30, 2022, Qilian is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. This notice has no immediate effect on the listing or trading of Qilian's ordinary shares on Nas
JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd ((the ", Company", NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of $0.05 per ordinary share, payable in cash on or about March 6, 2023, to shareholders of record on February 28, 2023. "Despite the impacts of COVID-19 on us in our last fiscal year, the Company maintained decent operating results and healthy cash flow. We expect better financial results as China announced a rollback of its anti-COVID measures." said Mr. Zhanchang Xin, CEO of the Company. About Qilian International Holding Group Ltd Q
JIUQUAN, China, Sept. 30, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the first six months of fiscal year 2022 ended March 31, 2022. Mr. Zhanchang Xin, Chairman and CEO of the Company, commented, "Under the impact of uncertain political climate and COVID-19 variants, the prices of agricultural and energy products have been increasing globally in 2022, which also led to reduced profitability of the manufacturing industry in general. Our half-year report in 2022 presents a revenue of approximately US$32.1 million, an increase of
6-K - Qilian International Holding Group Ltd (0001779578) (Filer)
6-K - Qilian International Holding Group Ltd (0001779578) (Filer)
EFFECT - Qilian International Holding Group Ltd (0001779578) (Filer)
F-3/A - Qilian International Holding Group Ltd (0001779578) (Filer)
6-K - Qilian International Holding Group Ltd (0001779578) (Filer)
S-8 - Qilian International Holding Group Ltd (0001779578) (Filer)
6-K - Qilian International Holding Group Ltd (0001779578) (Filer)
20-F - Qilian International Holding Group Ltd (0001779578) (Filer)
NT 20-F - Qilian International Holding Group Ltd (0001779578) (Filer)
6-K - Qilian International Holding Group Ltd (0001779578) (Filer)
JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd ((the ", Company", NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of $0.05 per ordinary share, payable in cash on or about March 6, 2023, to shareholders of record on February 28, 2023. "Despite the impacts of COVID-19 on us in our last fiscal year, the Company maintained decent operating results and healthy cash flow. We expect better financial results as China announced a rollback of its anti-COVID measures." said Mr. Zhanchang Xin, CEO of the Company. About Qilian International Holding Group Ltd Q
As Class A Ordinary Shares Close At $1.00 Or Greater For 10 Consecutive Days; Nasdaq Closes Compliance Matter
Shares of Helen of Troy Limited (NASDAQ:HELE) fell sharply during Tuesday's session after the company reported soft first-quarter earnings and lowered its FY25 guidance. Helen of Troy reported quarterly earnings of 99 cents per share which missed the analyst consensus estimate of $1.59. The company reported quarterly sales of $416.85 million which missed the analyst consensus estimate of $446.22 million, according to data from Benzinga Pro. Helen of Troy shares dipped 30.3% to $62.06 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Soligenix, Inc. (NASDAQ:SNGX) shares jumped 195% to $5.90 after the company announced interim results for extende
Qilian Intl Hldg Gr's (NYSE:QLI) short percent of float has risen 456.25% since its last report. The company recently reported that it has 43 thousand shares sold short, which is 2.67% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short inte
Gainers Innovative Eyewear (NASDAQ:LUCY) shares moved upwards by 421.5% to $0.97 during Monday's regular session. The company's market cap stands at $16.9 million. OneMedNet (NASDAQ:ONMD) shares moved upwards by 55.78% to $2.29. The company's market cap stands at $54.6 million. Qilian Intl Hldg Gr (NASDAQ:QLI) shares moved upwards by 37.59% to $0.91. The company's market cap stands at $32.4 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 29.7% to $0.18. The market value of their outstanding shares is at $4.0 million. TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 28.77% to $1.79. The company's market cap stands at $11.8 million. MultiPlan (NYSE:MPLN) stock rose 2
Gainers OneMedNet (NASDAQ:ONMD) shares moved upwards by 118.4% to $1.07 during Thursday's regular session. The market value of their outstanding shares is at $25.5 million. Renovaro (NASDAQ:RENB) stock rose 46.79% to $1.38. The company's market cap stands at $203.5 million. Altamira Therapeutics (NASDAQ:CYTO) shares increased by 29.37% to $1.85. The company's market cap stands at $4.1 million. Purple Biotech (NASDAQ:PPBT) stock rose 23.44% to $0.84. The company's market cap stands at $21.9 million. As per the press release, Q1 earnings came out 2 days ago. P3 Health Partners (NASDAQ:PIII) stock increased by 23.04% to $0.62. The market value of their outstanding shares is at $73.8 millio
Gainers Sharps Technology (NASDAQ:STSS) stock increased by 56.5% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $6.3 million. Geovax Labs (NASDAQ:GOVX) shares moved upwards by 21.71% to $2.27. The market value of their outstanding shares is at $5.2 million. NexImmune (NASDAQ:NEXI) stock increased by 9.52% to $3.45. The company's market cap stands at $4.7 million. As per the news, the Q1 earnings report came out 2 days ago. Cognition Therapeutics (NASDAQ:CGTX) stock rose 8.04% to $2.83. The market value of their outstanding shares is at $113.3 million. Clearside Biomedical (NASDAQ:CLSD) shares rose 7.39% to $1.45. The market value of t
Gainers Mustang Bio (NASDAQ:MBIO) stock increased by 51.6% to $0.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $5.8 million. NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 30.78% to $5.99. The market value of their outstanding shares is at $29.3 million. Rezolute (NASDAQ:RZLT) shares rose 25.0% to $3.75. The company's market cap stands at $150.5 million. Akso Health Group (NASDAQ:AHG) stock moved upwards by 16.26% to $1.0. The market value of their outstanding shares is at $146.6 million. Coeptis Therapeutics (NASDAQ:COEP) shares increased by 15.72% to $0.39. The company's market cap stands at $14.4 million. Qilian Intl Hldg Gr
Gainers Rezolute (NASDAQ:RZLT) stock increased by 52.7% to $4.58 during Tuesday's after-market session. The company's market cap stands at $183.8 million. The company's, Q3 earnings came out 4 days ago. Mustang Bio (NASDAQ:MBIO) stock increased by 30.64% to $0.41. The company's market cap stands at $5.0 million. The company's, Q1 earnings came out 4 days ago. Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 14.77% to $0.87. The company's market cap stands at $31.1 million. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by 12.68% to $2.31. The market value of their outstanding shares is at $4.9 million. The company's, Q4 earnings came out 4 days ago. Immunome (NASDAQ:IMNM) shares moved